Complete metabolic response following anaplastic lymphoma kinase (ALK) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence in situ hybridisation discordant ALK test results
- Author(s)
- Chazan, G; Forbes, D; Murugasu, A; Wong, HL; Solomon, B;
- Details
- Publication Year 2021-08,Volume 51,Issue #8,Page 1355-1356
- Journal Title
- Internal Medicine Journal
- Publication Type
- Case report
- Keywords
- *Adenocarcinoma/drug therapy/genetics; Anaplastic Lymphoma Kinase/genetics; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; *Lung Neoplasms/drug therapy/genetics; *Neoplasms, Unknown Primary
- Department(s)
- Medical Oncology
- PubMed ID
- 34423539
- Publisher's Version
- https://doi.org/10.1111/imj.15450
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-06-20 08:03:16
Last Modified: 2025-06-20 08:04:25